Press Releases EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			5-day change	1st Jan Change
8.47 ^USD	+3.80%		-9.70%	-63.35%

12/06	Transcript : EyePoint Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM
04/06	JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	18/06	AQ
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024	18/06	AQ
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	17/06	AQ
EyePoint Pharmaceuticals : Goldman Sachs Global Healthcare Conference Presentation	12/06	PU
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference	05/06	AQ
EyePoint Pharmaceuticals : Investor Presentation May 2024	28/05	PU
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	16/05	AQ
EyePoint Pharmaceuticals: Q1 Earnings Snapshot	08/05	AQ
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments	08/05	AQ
EyePoint Pharmaceuticals : PAVIA Topline Data Conference Call Presentation	06/05	PU
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy	06/05	AQ
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	17/04	AQ
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	16/04	AQ
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists	02/04	AQ
EyePoint Pharmaceuticals : Investor Presentation March 2024	22/03	PU
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	18/03	AQ
EyePoint Pharmaceuticals: Q4 Earnings Snapshot	07/03	AQ
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments	07/03	AQ
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer	04/03	AQ
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024	29/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Press Releases

Filters